[New strategies against autoaggressive immune system. Is rheumatism to be healable soon?].
Meissner
Thomas
T
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000628:therapy; D001182:Arthroscopy; D002478:Cells, Cultured; D019902:Chondrocytes / Q000637:transplantation; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000628:therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000188:drug therapy / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D012595:Scleroderma, Systemic / Q000628:therapy; D033581:Stem Cell Transplantation; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D016861:Cyclooxygenase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D008727:Methotrexate